



Rekvina
LABORATORIES LIMITED

At & Post : Dashrath, N.H. No 8, Dist Baroda-391 740 (Gujarat-India)
Admn. Office : 328-329, Third Floor, Paradise Complex, Sayajigunj, Baroda-390 005. (Gujarat-India)
Phone : +91-265-2362966, • Email : info@rekvinalaboratories.com • Web : www.rekvinalaboratories.com

Date: 30.01.2025

To,
Department of Corporate Services,
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort, Mumbai – 400 001.

Ref: Scrip Code: 526075

Subject: Integrated Filing (Financial) for the quarter and nine months ended on 31st December, 2024

Dear Sir/ Madam

Pursuant to SEBI Circular No. SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated December 31, 2024, read with BSE Circular No. 20250102-4 dated January 2, 2025, we are submitting herewith the Integrated Filing (Financial) for the quarter and nine months ended December 31, 2024.

This is for your information and records.

Thanking you,

Yours faithfully,

For Rekvina Laboratories Limited

Amit Mukesh Shah
Managing Director
DIN: 01993211

REKVINA LABORATORIES LIMITED
 Regd. Office: 328, Paradise Complex, Sayajigunj, Vadodara, Gujarat - 390005.
 Email: info@rekvinallaboratories.com CIN:L24231GJ1988PLC011458
 Un-audited Financial Results
For The Quarter and Nine Months Ended on 31st December 2024

	Particulars	Quarter ended			Nine Months ended		Year ended
		31-Dec-24	30-Sep-24	31-Dec-23	31-Dec-24	31-Dec-23	31-Mar-24
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	(Audited)
		(₹ in lakhs)					
I.	Revenue from Operations				-	-	-
II.	Other Income				-	-	-
III.	Total Income (I + II)				-	-	-
IV.	Expenses						
	(a) Cost of Materials Consumed				-	-	-
	(b) Purchase of Stock-in- Trade				-	-	-
	(c) Change In Inventories of finished goods, Work-In- Progress and Stock- In- Trade				-	-	-
	(d)Employee benefits expenses				-	-	-
	(e)Finance costs				-	-	-
	(f)Depreciation & Amortization Expenses				-	-	-
	(g) Provision for diminution in long investment				-	-	-
	(h)Other Expenses				-	-	-
	Total Expenses	2.43	6.65	0.43	9.42	1.43	1.64
V.	Profit/(Loss) before exceptional Items and tax (III-IV)	2.43	6.65	0.43	9.42	1.43	1.64
VI.	Exceptional Items	(2.43)	(6.65)	(0.43)	(9.42)	(1.43)	(1.64)
VII.	Profit/(Loss) before Tax (V - VI)	-	-	-	-	-	-
VIII.	1) Tax expenses Current Tax	-	-	-	-	-	-
	2) Deferred Tax	-	-	-	-	-	-
	Total Tax Expenses	-	-	-	-	-	-
IX.	Profit / (Loss) for the period from continuing operations (VII-VIII)	(2.43)	(6.65)	(0.43)	(9.42)	(1.43)	(1.64)
X.	Profit/(loss) from discontinued operations	-	-	-	-	-	-
XI.	Tax expenses of discontinued operations	-	-	-	-	-	-
XII.	Profit/(loss) from discontinued operations (after tax) (X-XI)	-	-	-	-	-	-
XIII.	Net Profit/(Loss) for the period (IX+XII)	(2.43)	(6.65)	(0.43)	(9.42)	(1.43)	(1.64)
XIV.	Other comprehensive income						
	A (i) Items that will not be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-
	B (i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-
XV.	Total Comprehensive Income for the period (XIII+XIV) (Comparing Profit/(Loss) and other Comprehensive Income for the period)	(2.43)	(6.65)	(0.43)	(9.42)	(1.43)	(1.64)
XVI.	Earning per equity share						
	1) Basic	(0.040)	(0.110)	(0.007)	(0.156)	(0.024)	(0.027)
	2) Diluted	(0.040)	(0.110)	(0.007)	(0.156)	(0.024)	(0.027)

1. The Above Standalone Quarterly Financial Results have been reviewed and recommended by the Audit Committee and the same has been approved by the Board of Directors of the Company at its meeting held on **20-01-2025**.

2. As the Company's business activity falls within a single primary business segment, namely dealing in Trading of Goods, the disclosure requirements as per Ind-AS 108 "operating segments" are not applicable.

3. The Earing Per Shares has been computed in accordance with Accounting Standard on Earing Per Shares (AS 20).

4. Previous period figures have been regrouped/reclassified wherever necessary to confirm with the current periods classification/disclosure.

5. This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (IND AS) prescribed under section 133 of the Companies Act, 2013 read with rule 3 of the Companies (Indian Accounting Standard) Rules, 2016 and Companies (Indian Accounting Standard) (Amendment) Rules, 2016.

6. The Company does not has any lease contract, hence, IND-AS 116 is not applicable.

By Order of the Board of Directors
For Rekvina Laboratories Limited

Place:- Vadodara
Date:- 30-01-2025

Mr. Amit Mukesh Shah
Managind Director
DIN: 01993211



B. STATEMENT ON DEVIATION OR VARIATION FOR PROCEEDS OF PUBLIC ISSUE, RIGHT ISSUE, PREFERENTIAL ISSUE, QUALIFIED INSTITUTIONS PLACEMENT ETC.: - NOT APPLICABLE

C. FORMAT FOR DISCLOSING OUTSTANDING DEFAULT ON LOANS AND DEBT SECURITIES:

S. No.	Particulars	In INR Code
1.	Loans/ revolving facilities like cash credit from banks/ financial institution	
A	Total amount outstanding as on date	0
B	Of the total amount outstanding, amount of default as on date	0
2.	Unlisted debt securities i.e., NCDs and NCRPS	
A	Total amount outstanding as on date	0
B	Of the total amount outstanding, amount of default as on date	0
3.	Total financial indebtedness of the listed entity including short term and long term	0

D. FORMAT FOR DISCLOSURE OF RELATED PARTY TRANSACTIONS (applicable only for half-yearly filing i.e., 2nd and 4th quarter): NOT APPLICABLE

E. STATEMENT ON IMPACT OF AUDIT QUALIFICATION (FOR AUDIT REPORT WITH MODIFIED OPINION) SUBMITTED ALONG-WITH ANNUAL AUDITED FINANCIAL RESULT (Standalone and Considered separately) (applicable only for Annual Filing i.e., 4th quarter): NOT APPLICABLE

Yours faithfully,

For Rekvina Laboratories Limited

Amit Mukesh Shah
Managing Director
DIN: 01993211

Date: 30.01.2025

Independent Auditor's Review Report on the Quarter and Nine Months Ended Un-Audited Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

Review Report to The Board of Directors


Rekvina Laboratories Limited.

1. We have reviewed the accompanying statement of unaudited standalone financial results of Rekvina Laboratories Limited (the "Company") for the 3rd quarter and Nine months Ended 31st December 2024 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. CIR/CFD/CMD1/44/2019, dated 29-03-2019. (The Circular).
2. The preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting (IND AS 34) prescribed under Section 133 of the Companies Act, 2013 read with Rule 3 of Companies (Indian Accounting Standards) Rules, 2013 read with SEBI Circular No. CIR/CFD/CMDI/44/2019, is the responsibility of the Company's management and has been taken on record by the Board of Directors of the Company. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review in accordance with the Standard on Review Engagements (SRE) 2014, Review of Interim Financial Information Performed by the Independent Auditor of the Entity issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards (IND AS) specified under Section 133 of the Companies Act, 2013, read with relevant rules issued there under and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, including the manner in which it is to be disclosed or that it contains any material misstatement.
5. The accompanying INDAS financial results and other financial information for the corresponding quarter ended 31-12-2024, have been subject to a limited review or audit and based on the information compiled by Management and has been taken on record by the Board of Directors.

Date: 20/01/2025
Place: Vadodara



FOR Y. M. SHAH & CO.
CHARTERED ACCOUNTANTS
Firm Reg. No. : 114124W


Partner
Harsh Shah
M. No. 188123

UDIN: 25188123 BAKXAA
6859